A Phase 1b Dose Escalation and Dose Expansion Study of ONO/GS-4059 in Combination With Other Targeted Anti-cancer Therapies in Subjects With B-cell Malignancies
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Tirabrutinib (Primary) ; Entospletinib; Idelalisib
- Indications B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 02 Jun 2017 Preliminary results (n=32) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 28 Apr 2017 Planned End Date changed from 1 Oct 2021 to 1 Jul 2023.
- 28 Apr 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2020.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History